Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margreet G Franken

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Health Policy (Amsterdam, Netherlands)|May 1, 2013
Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over timeFrank G Sandmann, Margreet G Franken, Adri Steenhoek, et al.
Pharmacoeconomics|February 4, 2015
A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registryHedwig M Blommestein, Margreet G Franken, Carin A Uyl-de Groot
BMC Family Practice|February 19, 2018
The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenariosMargreet G Franken, Isaac Corro Ramos, Jeanine Los, et al.
Nederlands Tijdschrift Voor Geneeskunde|January 26, 2011
[New drugs: money-back guarantee?]Adri Steenhoek, Marc A Koopmanschap, Margreet G Franken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple MyelomaChrissy H Y van Beurden-Tan, Margreet G Franken, Hedwig M Blommestein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2010
The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematologySiok Swan Tan, Chantal W M Van Gils, Margreet G Franken, et al.
Haematologica|January 5, 2019
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysisHedwig M Blommestein, Chrissy H Y van Beurden-Tan, Margreet G Franken, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanomaMargreet G Franken, Brenda Leeneman, Maria Gheorghe, et al.
Anti-Cancer Drugs|May 31, 2018
Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the NetherlandsMargreet G Franken, Tim A Kanters, Jules L Coenen, et al.
Health Policy (Amsterdam, Netherlands)|December 6, 2014
Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursementJennifer G Gaultney, Margreet G Franken, Carin A Uyl-de Groot, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Health Policy (Amsterdam, Netherlands)|May 1, 2013
Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over timeFrank G Sandmann, Margreet G Franken, Adri Steenhoek, et al.
Pharmacoeconomics|February 4, 2015
A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registryHedwig M Blommestein, Margreet G Franken, Carin A Uyl-de Groot
BMC Family Practice|February 19, 2018
The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenariosMargreet G Franken, Isaac Corro Ramos, Jeanine Los, et al.
Nederlands Tijdschrift Voor Geneeskunde|January 26, 2011
[New drugs: money-back guarantee?]Adri Steenhoek, Marc A Koopmanschap, Margreet G Franken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple MyelomaChrissy H Y van Beurden-Tan, Margreet G Franken, Hedwig M Blommestein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2010
The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematologySiok Swan Tan, Chantal W M Van Gils, Margreet G Franken, et al.
Haematologica|January 5, 2019
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysisHedwig M Blommestein, Chrissy H Y van Beurden-Tan, Margreet G Franken, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanomaMargreet G Franken, Brenda Leeneman, Maria Gheorghe, et al.
Anti-Cancer Drugs|May 31, 2018
Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the NetherlandsMargreet G Franken, Tim A Kanters, Jules L Coenen, et al.
Health Policy (Amsterdam, Netherlands)|December 6, 2014
Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursementJennifer G Gaultney, Margreet G Franken, Carin A Uyl-de Groot, et al.
Pageof 3